Why Does Heart Risk Change During Menopause, and What Should You Actually Measure?

The short answer

Why does cardiovascular risk shift during the menopause transition?

Most women I talk with assume heart risk is a post-menopause problem. Something that shows up in your 60s, after the hot flashes are over, and gets handled with a statin conversation at some point down the road.

The research points somewhere else. The change appears to start earlier, in the years when periods are still happening but getting unpredictable.

The American Heart Association put out a scientific statement on this in 2020, "Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention". The core argument is that the menopause transition is its own risk window, separate from chronological aging, and that waiting until after menopause to intervene means acting after several of the changes have already happened.

What tends to change, based on the current literature:

Lipids move first and move fast. Total cholesterol, LDL cholesterol and apolipoprotein B (ApoB) commonly rise across the transition. Research on dyslipidemia across the menopause transition describes this as a distinct trajectory rather than a slow drift with age. The European Society of Cardiology has also highlighted menopause-associated changes in the blood fat profile as a potential mechanism linking menopause to cardiovascular outcomes.

Fat relocates. The same weight on the scale can sit differently. Visceral fat, the kind packed around organs, tends to increase during the transition even in women whose total weight barely changes. That's one reason the scale is a poor instrument here.

Insulin sensitivity tends to decline. Fasting insulin and A1c can drift upward before anything gets labeled prediabetes.

Blood pressure and vascular stiffness tend to increase. Reviews of cardiometabolic changes in the menopause transition and the broader role of menopause in the development of cardiovascular disease in women describe these as consistent, though the size of the effect varies a lot between individuals.

None of that is a diagnosis, and none of it means anything bad is guaranteed to happen. It means the slope changes, and a single snapshot at one point in time can miss the slope entirely.

What did the 2026 research actually find?

This is the study that made me want to write this post.

Published May 13, 2026 in the Journal of the American Heart Association, researchers analyzed 9,248 women aged 18 to 80 from the National Health and Nutrition Examination Survey (NHANES), 2007 through 2020. They scored cardiovascular health using the AHA's Life's Essential 8 framework, which combines diet, activity, nicotine exposure, sleep, weight, cholesterol, blood sugar and blood pressure into a single number.

The scores dropped in sequence. Median Life's Essential 8 score was 73.3 in premenopausal women, 69.1 in perimenopausal women, and 63.9 in postmenopausal women.

Perimenopausal women were roughly twice as likely as premenopausal women to land in the low cardiovascular health category. Drilling into components, perimenopausal women showed a 76% higher likelihood of a low cholesterol score and an 83% higher likelihood of a low blood sugar score.

The AHA's own writeup framed it as a window of opportunity for heart disease prevention, which is a more useful frame than the alarm-bell version.

Two honest caveats. This is cross-sectional survey data, which means it shows associations across groups, not cause and effect in an individual. And menopause staging in survey data is imperfect. The finding lines up with a decade of longitudinal work pointing the same direction, but one study is one study.

Why do "normal" labs miss this?

Here's the part that frustrates me, and it's the same frustration that shows up in almost every intake conversation I have.

A standard lipid panel gives you total cholesterol, HDL, triglycerides and a calculated LDL. That panel was designed for population screening, and it does that job reasonably well. What it doesn't do is tell you how many atherogenic particles are circulating, whether you inherited an elevated Lp(a), or where your insulin sits before your glucose ever budges.

So you can be 47, feeling worse than you did at 42, with a lipid panel that comes back flagged "within normal limits," and walk out with no information about the thing that's actually changing.

That gap isn't anyone's fault. Reference ranges are built from the population that got tested, and most people getting tested aren't metabolically healthy. Normal and optimal are different questions, and a screening panel is answering the first one.

Adding a few markers changes the picture:

ApoB. One ApoB molecule rides on each atherogenic particle, so ApoB is a direct particle count rather than a cholesterol-content estimate. When LDL cholesterol and ApoB disagree, current evidence generally favors ApoB as the better risk marker.

Lp(a). Largely genetically determined, stable across life, and typically measured once. Many people never have it checked. If it's elevated, that changes the whole risk conversation with your provider, and it's family information too.

Fasting insulin and A1c together. Insulin frequently rises years before glucose does. Looking at glucose alone is looking at the smoke alarm and ignoring the stove.

Blood pressure, tracked properly. Not one reading in a paper gown after you rushed across a parking lot.

Body composition. Where the fat is matters more than what the scale says.

At Vitality Dartmouth this is the reasoning behind our genomic and lab biomarker testing: read the actual data, including markers a standard panel skips, then build a plan around what's there instead of guessing.

To be clear on scope, because it matters: I'm an RN. I build the program, coach the training, and translate the data. Our collaborating NP or MD orders labs and writes any prescriptions. That division is the point, not a technicality.

What can you actually do about it?

The uncomfortable truth is that the interventions with the strongest data aren't exotic.

Resistance training. Muscle is metabolically active tissue, and it's the lever with the best evidence behind it for midlife women. Cardio has its place. It isn't the main event here.

Protein intake that's actually adequate. Most women I work with are eating considerably less than they think.

Sleep, treated as a clinical variable. Sleep fragmentation during the transition feeds insulin resistance and blood pressure both.

Blood pressure and lipids managed with a prescriber, when the numbers call for it. If your ApoB or blood pressure warrants medication, that's a conversation with a provider, not something a wellness program substitutes for.

Hormone therapy where appropriate, decided with a prescriber. The 2020 AHA statement is explicit that hormone therapy is not recommended as a cardiovascular prevention strategy. Whether it's right for symptoms is a separate, individual, provider-led decision.

Our Genomic Menopause Reset is built around the measurable side of this: baseline testing, a training and nutrition plan matched to what the data shows, and repeat labs so you can see whether the numbers moved. Where medically supervised weight loss is part of the plan, the medication is provider-prescribed and monitored, and it runs alongside strength training and lab follow-up rather than instead of them. Some therapies in functional and wellness medicine are prescribed off-label, meaning used outside their FDA-approved indication. That's a legitimate practice under a licensed prescriber, and you should always be told when it applies to you.

Does this matter differently on the SouthCoast?

Access is the local variable.

Dartmouth, New Bedford, Westport, Fairhaven and Fall River are not short on healthcare. What's harder to find here is somebody who'll sit down with a full panel, explain what ApoB means in plain language, and check it again in 12 weeks to see if anything changed. Most women I meet from the SouthCoast have been through a 12-minute visit, a "your labs are normal," and a referral list.

The alternative most people get pushed toward is a telehealth subscription. I've looked at roughly 20 local, regional and national telehealth weight loss companies. Not one offers an in-person lab review. In month 4, nobody there knows your name.

Being in your town means the follow-up visit is a 15-minute drive, not a video window that closes on schedule.

Frequently asked questions

Ready to talk it through?

If you're in Dartmouth or anywhere on the SouthCoast and you've been told your labs are normal while you feel like something changed, get a baseline you can actually track. Book a free discovery call and we'll talk through what's worth measuring in your situation.

You can read more of our education articles here.

Educational disclaimer: This article is for general educational purposes only and is not medical advice, diagnosis, or treatment. It does not establish a clinician-patient relationship. Individual results vary and no outcome is guaranteed. Justin Coelho is a Registered Nurse; he does not diagnose or prescribe. All laboratory orders and prescriptions at Vitality Dartmouth are written by a collaborating nurse practitioner or physician. Some therapies discussed in functional and wellness medicine are prescribed off-label or remain investigational. Always talk with your own licensed healthcare provider before making changes to your care, and do not stop or start any medication without their guidance.